Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On May 3, 2017, Accelerate Diagnostics, Inc. issued a press
release announcing its preliminary financial results of
operations for the quarter ending March 31, 2017 and hosted a
conference call to discuss such results. A copy of the press
release is attached hereto as Exhibit 99.1 and a copy of the
transcript of the conference call is attached hereto as Exhibit
99.2.
In accordance with General Instruction B.2 for Form 8-K, the
information in this Item 2.02, including Exhibit 99.1 and Exhibit
99.2, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such
filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) |
Exhibits.The following materials are filed as exhibits to this Current Report on Form 8-K: |
| Exhibit | ||
| Number | Description | |
| 99.1 |
Press Release, dated May 3, 2017 |
|
| 99.2 | Preliminary Earnings Call Transcript, May 3, 2017 |
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session up +0.25 at 29.50 with 449,260 shares trading hands.